Stockscreener 앱 받기
2.78
2.46%
-0.07
시장 영업 전:
2.78
전일 마감가:
$2.85
열려 있는:
$2.79
하루 거래량:
18,322
Relative Volume:
0.27
시가총액:
$987.42M
수익:
$863.66M
순이익/손실:
$-225.27M
주가수익비율:
-4.3835
EPS:
-0.6342
순현금흐름:
$-63.28M
1주 성능:
-2.46%
1개월 성능:
-1.07%
6개월 성능:
-24.46%
1년 성능:
-33.97%
1일 변동 폭
$2.73
$2.79
1주일 범위
$2.73
$2.93
52주 변동 폭
$2.308
$4.415
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
2.78 | 1.01B | 863.66M | -225.27M | -63.28M | -0.6342 |
TAK
Takeda Pharmaceutical Co Adr
|
16.75 | 52.93B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.75 | 42.94B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.24 | 38.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.10 | 31.48B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
554.34 | 23.53B | 3.17B | 1.29B | 1.01B | 27.09 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 재개 | H.C. Wainwright | Buy |
| 2026-02-03 | 개시 | Berenberg | Buy |
| 2025-04-24 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-10-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-08-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-07-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-04-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-06-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-04-04 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-11-16 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | 재개 | Cowen | Outperform |
| 2022-01-07 | 재개 | Citigroup | Neutral |
모두보기
Evotec Se Adr 주식(EVO)의 최신 뉴스
Evotec stock. Thin source set keeps the focus on business context. - Ad-hoc-news.de
EVTA Forecast — Price Target — Prediction for 2027 - TradingView
100% Profit Potential in Sight: Vidac Pharma's Chance to Double vs Bayer and Evotec - news.financial
Weight-Loss Injections, Cancer Cell Inhibitors & the Power of Algorithms: Adding Potential to Your Portfolio with Novo Nordisk, Vidac Pharma, and Evotec - news.financial
Evotec consensus picture on Wall Street, shares trade as ADR on NASDAQ - Ad-hoc-news.de
Evotec launches J.TRAIN for biologics manufacturing - grafa.com
Evotec consensus picture on Nasdaq EVO, shares hover around 2.74 dollars - Ad-hoc-news.de
A0QZ3J Forecast — Price Target — Prediction for 2027 - TradingView
Evotec SE Sponsored ADR Actuals & Estimates (NASDAQ:EVO) - TradingView
Evotec refines analyst expectations, shares trade under 5 euros on Xetra - AD HOC NEWS
Evotec shows weak June performance, analyst consensus points above current shares - AD HOC NEWS
Evotec Stockweekly review and sector comparison - Ad-hoc-news.de
Which stock to buy now? Evotec, Nel, and Lahontan Gold in focus - news.financial
Evotec (EVO) Stock Price, News & Analysis $EVO - MarketBeat
Evotec SE Stock (DE0005664809): Short Interest Eases While Shares Trade Near Lows - AD HOC NEWS
Earnings call transcript: Evotec Q1 2026 sees revenue drop amid market challenges - Investing.com
Evotec Q1 2026 slides: revenue drops 22% as transformation accelerates - Investing.com
Evotec reports wider quarterly loss, misses revenue expectations By Investing.com - Investing.com Nigeria
Evotec SE stock (DE0005664809): After CEO exit and audit delay, investors watch turnaround plans - AD HOC NEWS
EVOEvotec SE ADR Stock Price and Quote - Finviz
Evotec ADR Slides 4.3% as Selling Pressure Tests Key Support LevelsQuality Factor - The Legal Advocate
Takeover Candidates for 2026! The Life Sciences Sector Is Heating Up: Evotec, BioNxt Solutions, BioNTech, and Formycon in Focus! - news.financial
BUY RECOMMENDATIONS for RENK and Desert Gold! SHOCK for Evotec! - news.financial
Evotec SE stock (DE0005664809): Steady FY 2025 results amid US expansion - AD HOC NEWS
Evotec AG Earnings Call Balances Pain With Promise - The Globe and Mail
Evotec SE stock (DE0005664809): Drug discovery leader eyes US biotech growth - AD HOC NEWS
Evotec places €116.1 million convertible bonds due 2033 - Investing.com UK
Evotec places €116.1 million convertible bonds due 2033 By Investing.com - Investing.com South Africa
Evotec SE stock (DE0005664809): Recent price gains signal short-term momentum - AD HOC NEWS
Evotec SE stock (DE0005664809): HC Wainwright cuts Q2 earnings outlook - AD HOC NEWS
Boyd Gaming posts downbeat Q1 results, joins Coursera, Evotec and other big stocks moving lower in Friday's pre-market session - MSN
Evotec SE stock (DE0005664809): Q1 2026 results show sharp revenue drop amid restructuring - AD HOC NEWS
Take note! The stock market is (still) ignoring key developments at Desert Gold, Evotec, and Mutares! - news.financial
Evotec Q1 2026 slides: revenue drops 22% as transformation accelerates By Investing.com - Investing.com Nigeria
Earnings call transcript: Evotec Q1 2026 sees revenue drop amid market challenges By Investing.com - Investing.com South Africa
Evotec reports wider quarterly loss, misses revenue expectations - Investing.com
Evotec's Share Price Surges! Summer Rally for Desert Gold? Rheinmetall Shares Heading Toward EUR 2,000? - news.financial
Evotec & Almirall nominate dermatology development candidate - grafa.com
Evotec SE Stock (DE0005664809): Q1 2026 Results Due Today - AD HOC NEWS
Evotec Se Adr (EVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.68%
0.20%
자본화:
|
볼륨(24시간):